Jill brings more than 20 years of scientific expertise and a broad background in immuno-oncology and cell-based therapeutics for cancer, as well as synthetic biology and process development for cell therapy. Jill leads the Cellular Engineering, Immunotherapy and Early Clinical Development functions at ElevateBio.
Prior to ElevateBio, Jill was Head of Synthorx, a Sanofi Company, where she was responsible for the integration of the company’s platform into the Global Sanofi Large Molecule Research organization. In addition, she led the Synthorx team, managing its pipeline focused on immuno-oncology and immunology & inflammation, including the development THOR-809 from discovery to first-in-human trials in under three years. Prior to Synthorx, Jill held various senior positions at Fate Therapeutics, Adaptive Biotechnologies and Janssen Research and Development, where her work was the subject of five patent applications.
Education and Accomplishments
Jill received her Ph.D. in immunology from the University of Texas Southwestern Medical Center, and B.S. in Biochemistry and Biophysics from Oregon State University.